Cereblon - nový terapeutický ciel' v liečbe mnohopočetného myelómu
| Autoři | |
|---|---|
| Rok publikování | 2014 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Klinická onkologie |
| Fakulta / Pracoviště MU | |
| Citace | |
| Doi | http://dx.doi.org/10.14735/amko2014326 |
| Obor | Onkologie a hematologie |
| Klíčová slova | cereblon; multiple myeloma; immunomodulatory drugs |
| Popis | Treatment of multiple myeloma (MM), currently an incurable disease, aims to achieve complete remission. Immunomodulatory drugs (IMiDs), represented by thalidomide, are one class of very effective drugs. However, the mechanism of IMiDs action is not yet completely understood. Recent research suggests that cereblon (CRBN) plays an important role in mediating anti-tumor effects of IMiDs; therefore, our review focuses on this protein. CRBN is a substrate receptor of Cul4-E3 ubiquitin ligase complex, and thus recognizes proteins destined for degradation. Binding of CRBN and IMiDs inhibits function of the entire ubiquitin-proteasome complex which partly explains their anti-tumor effects. In addition, a correlation between CfiB/V gene expression and effectiveness of treatment in MM patients treated with IMiDs was confirmed. These findings suggest that CRBN expression could possibly serve as a biomarker to predict response to IMiD in MM patients. |